Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


November SMC decisions

The Scottish Medicines Consortium (SMC) has published its November 2014 decisions on medicines to be used in NHS Scotland. Aflibercept (Eylea), daclatasvir (Daklinza), everolimus (Afinitor), ipilimumab (Yervoy) and saxagliptin (Onglyza) have been recommended for use in NHS Scotland. Pertuzumab (Perjeta) has been rejected for use in NHS Scotland. Further information is available on the SMC’s website in the November 2014 briefing note.  

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067169

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.